<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE4FA0EC-37EA-4B26-BA91-4528C959C227"><gtr:id>CE4FA0EC-37EA-4B26-BA91-4528C959C227</gtr:id><gtr:name>Gustave-Roussy Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6EF3B963-88BD-4EA0-BDFE-60C742501F07"><gtr:id>6EF3B963-88BD-4EA0-BDFE-60C742501F07</gtr:id><gtr:name>Memorial Sloan Kettering Cancer Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D657B59F-F040-46B5-A35B-D457C06CE596"><gtr:id>D657B59F-F040-46B5-A35B-D457C06CE596</gtr:id><gtr:name>Becton, Dickinson and Company (BD)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F"><gtr:id>F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F</gtr:id><gtr:name>Celgene</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8"><gtr:id>3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8</gtr:id><gtr:name>Stanford University</gtr:name><gtr:address><gtr:line1>450 Serra Mall</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/274F2FB0-27BB-4991-A894-796A2AE916E3"><gtr:id>274F2FB0-27BB-4991-A894-796A2AE916E3</gtr:id><gtr:name>The Christie NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Wilmslow Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M20 4BX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE4FA0EC-37EA-4B26-BA91-4528C959C227"><gtr:id>CE4FA0EC-37EA-4B26-BA91-4528C959C227</gtr:id><gtr:name>Gustave-Roussy Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6EF3B963-88BD-4EA0-BDFE-60C742501F07"><gtr:id>6EF3B963-88BD-4EA0-BDFE-60C742501F07</gtr:id><gtr:name>Memorial Sloan Kettering Cancer Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D657B59F-F040-46B5-A35B-D457C06CE596"><gtr:id>D657B59F-F040-46B5-A35B-D457C06CE596</gtr:id><gtr:name>Becton, Dickinson and Company (BD)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F"><gtr:id>F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F</gtr:id><gtr:name>Celgene</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8"><gtr:id>3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8</gtr:id><gtr:name>Stanford University</gtr:name><gtr:address><gtr:line1>450 Serra Mall</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/274F2FB0-27BB-4991-A894-796A2AE916E3"><gtr:id>274F2FB0-27BB-4991-A894-796A2AE916E3</gtr:id><gtr:name>The Christie NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Wilmslow Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M20 4BX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/195C7B40-323D-45D5-9EAD-7B0E02AEDB2E"><gtr:id>195C7B40-323D-45D5-9EAD-7B0E02AEDB2E</gtr:id><gtr:firstName>Paresh</gtr:firstName><gtr:surname>vyas</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12009%2F11"><gtr:id>9C526D6C-9951-43E8-96C1-BD13AD31DEAA</gtr:id><gtr:title>Identification, characterisation and therapeutic targeting of leukaemic stem/propagating cells in Acute Myeloid Leukaemia</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12009/11</gtr:grantReference><gtr:abstractText>There are ~3000 new cases a year in the UK of Acute Myeloid Leukaemia (AML). This is the most common aggressive leukaemia. Despite advances in treating patients under the age of 60 years, 50% of these patients still die of their disease. Furthermore, 80% of patients are over the age of 60 and in this age group only 5% of patients are cured. Thus, we need to improve therapy. 

AML mainly arises sporadically through acquisition of genetic changes in DNA in multiple genes that regulate the complex process of blood cell production. In some patients there is a preleukaemia condition called Myelodysplasia (MDS). One way to further our understanding AML is to define the compendium of genetic changes throughout all our DNA in both AML and MDS and assess how changes deregulate normal blood stem and progenitor cells and transform them into cancerous populations. This necessary information provides a rational platform for future developments to directly benefit patient care. Furthermore study of MDS and AML provides a model to discover general principles in cancer biology and therapy.</gtr:abstractText><gtr:technicalSummary>Our aim is to characterise the heterogeneous populations of leukaemia propagating cells (LPC) in adult and childhood Acute Myeloid Leukaemia (AML) at functional, genetic, epigenetic and molecular levels, eventually at a single cell level, to improve our basic understanding of leukaemia initiation and propagation. The ultimate aim is to translate this knowledge to improve survival rates in patients.
Recent studies from our laboratory and other laboratories have shown that, within any one patient?s tumour, there is functional, molecular and genetic heterogeneity of tumour propagating populations. Though not yet formally demonstrated, layered upon this will likely be epigenetic heterogeneity. 
Thus, our key questions centre around understanding: a) the nature of this heterogeneity; b) how it arises and c) how different aspects of heterogeneity impact on each other. 
From a tumour biology perspective, a central hypothesis we will work towards testing is that there are specific molecular attributes present in AML LPC, but absent in downstream progeny, that explain LPC?s ability to propagate tumours whereas downstream progeny cannot. 
Experimentally, these studies will initially be cell population based. We will purify distinct immunophenotypic primary human AML populations, test their in vivo function, and determine their molecular, genetic and epigenetic profiles. This will be an iterative process. But, ultimately, these studies will have to be conducted at the single cell level,. To begin with, we will overlay single cell molecular and genetic analysis on the cell population-based studies. 
From a translational standpoint, our key hypotheses are: A) AML LPC are the chemoresistant relapse-driving populations. B) LPC can be therapeutically targeted. Only if both hypotheses are proven correct will be able to improve survival for patients.
To test the first hypothesis, we will track LPC from diagnosis through therapy. To address the second hypothesis, we will continue work with Stanford to develop a combination of therapeutic antibodies targeting LPC antigens. Once again, there are huge challenges here, that include: a) defining a window between efficacy and toxicity given that many LPC markers are widely expressed b) defining cocktails of antibodies that target all chemoresistant LPCs.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1044000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medical, Veterinary and Life Sciences</gtr:department><gtr:description>Biology of leukaemia stem cells in CML blast crisis.</gtr:description><gtr:id>E34C12E1-736F-47C8-82EF-BE4D4A734BD9</gtr:id><gtr:impact>Publication - Kinstrie R*, Karamitros D* Goardon N, Morrison H, Hamblin M, Robinson L, Clark RE, Copland M*, and Vyas P*. Heterogeneous Leukemia Stem Cells In Myeloid Blast Phase Chronic Myeloid Leukemia. Blood Advances (2016 in press).</gtr:impact><gtr:outcomeId>56d465637d24e8.25751498-1</gtr:outcomeId><gtr:partnerContribution>FISH analysis</gtr:partnerContribution><gtr:piContribution>Fuctional and clonal evaluation of LSC's</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Stem Cell Institute Stanford</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>57E9D7A6-13D0-43D1-B030-96022F1D9756</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-1</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Molecular Haematology Unit</gtr:department><gtr:description>MLL-AF9 acute myeloid leukaemia</gtr:description><gtr:id>2F5C9D41-14C5-4839-BA9D-D6A6B8B44AFD</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>545fcfadbd1625.23751128-1</gtr:outcomeId><gtr:partnerContribution>My partner Dr Milne will be co-joint supervisor</gtr:partnerContribution><gtr:piContribution>I will be joint principal supervisor on this project to study MLL Gene targets in AML.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Memorial Sloan Kettering Cancer Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Mutant IDH inhibition therapy in AML.</gtr:description><gtr:id>4F868865-E836-4AF1-BF3C-87443359FE88</gtr:id><gtr:impact>Grant income - 2015-2017 Celgene Fellowship in Myeloid Malignancy &amp;pound;423 141
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia
 
Eytan M. Stein, MD1*, Courtney D. DiNardo, MD2*, Daniel A. Pollyea, MD, MS3, Amir T. Fathi, MD4, Gail J. Roboz, MD5, Jessica K. Altman, MD6, Richard M. Stone, MD7, Daniel J. DeAngelo, MD, PhD7, Ross L. Levine, MD1, Ian W. Flinn, MD, PhD8, Hagop M. Kantarjian, MD2, Robert Collins, MD9, Manish R. Patel, MD10, Arthur E. Frankel, MD6, Anthony Stein, MD11, Mikkael A. Sekeres, MD, MS12, Ronan T. Swords, MD, PhD13, Bruno C. Medeiros, MD14, Christophe Willekens, MD15, Paresh Vyas, MD16,Alessandra Tosolini, BS17, Qiang Xu, PhD17, Robert D. Knight, MD17, Katharine E. Yen, PhD18, Sam Agresta, MD18, St&amp;eacute;phane De Botton, MD, PhD15?, and Martin S. Tallman, MD1? 

Submitted.
Enasidenib Induces Acute Myeloid Leukemia Cell Differentiation to Promote Clinical Response
Michael D. Amatangelo1?, Lynn Quek2?, Alan Shih3?, Eytan M. Stein3, Mikhail Roshal3, Stephane de Botton4, Benoit Marteyn5, Noushin Rahnamay Farnoud6, Muriel David7, Katharine E. Yen8, Martin S. Tallman3, Elli Papaemmanuil6,9, Virginie Lacronique-Penard4, Anjan Thakurta1*, Paresh Vyas2*, Ross L. Levine3,6,10*

Submitted.</gtr:impact><gtr:outcomeId>56d464ec73bef7.31662269-3</gtr:outcomeId><gtr:partnerContribution>Contributed samples and intellectual input</gtr:partnerContribution><gtr:piContribution>Mutant IDH inhibition therapy in AML.
Understanding mechanisms of response and resistance to targeted IDH inhibitor therapy in AML</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Haematology</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>253310B6-03C7-4867-8E2A-AA19C26CC6E2</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-3</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds Teaching Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Clinical Haematology</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>B43DD81B-29B0-4D38-AB00-936E944B7D43</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-4</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration on therapy of high risk MDS and AML.</gtr:description><gtr:id>11E438BB-7E4B-4B5B-BA59-E46B30FBFD67</gtr:id><gtr:impact>Quek L*, Ferguson P*, Metzner M, Ahmed I, Kennedy A, Garnett C, Jeffries S, Walter C, Piechocki K, Timbs A, Danby R, Raghavan M, Peniket A, Griffiths M, Bacon A, Ward J, Wheatley K, Vyas P*, Craddock C*. Mutational Analysis of Disease Relapse in Patients Allografted for Acute Myeloid Leukemia

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS, Freeman SD. Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia PLoS One. 2016 Sep 26;11(9):e0163291. PMID: 27669008

Craddock C, Jilani NY, Siddique S, Yap C, Khan JN, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, Vyas P, Goodyear OC, Tholouli E, Crawley C, Russell N, Byrne J, Malladi R, Snowden JA, Dennis M. Tolerability and clinical activity of post-transplant Azacitidine in patients allografted for Acute Myeloid Leukaemia treated on the RICAZA trial. Biol Blood Marrow Transplant. Sep 9. pii: S1083-8791(15)00609-6. doi: 10.1016/j.bbmt.2015.09.004. (2015).

Bradbury C, Houlton AE, Akiki S, Gregg R, Rindl M, Khan J, Ward J, Khan N, Griffiths M, Nagra S, Hills R, Burnett A, Russell N, Vyas P, Grimwade D, Craddock C, Freeman SD. Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia. Leukemia. 29 p988-91. (2014) PMID:25425198.

Craddock C, Goardon N, Quek L, Freeman S, Siddique S, Raghavan M, Schuh A, Grimwade D, Virgo P, Hills R, McSkeane T, Arrazi J, Gilkes A, Knapper, Adam Ivey, Brookes C, Miles O, Davies B, Chaudhury S, Pollard T, Price A, Atzberger A, Wall K, Kaur H, Griffiths M, Cavenagh, Majeti R, Weissman I, Burnett A, Vyas P. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukaemia 27:p1028-36 (2013). 

Goodyear O, Dennis M, Loke J, Jilani N, Siddique S, Ryan G, J Nunnick, Khanum R, Raghavan M, Cook M, Snowden J, Griffiths M, Russell N, Yin J, Crawley C, Cook G, Vyas P, Moss P, Malladi R, Craddock C. Azacitidine Induces Expansion of Regulatory T Cells and Induces a Tumor Antigen Specific Response after Allogeneic Stem Cell Transplantation in patients with AML. Blood. 119: p3361-9. (2012).

Co-administration of Vorinostat Does Not Improve Outcome of Patients with of Acute Myeloid Leukemia Treated with Azacitidine

Charles Craddock, MD, PhD1, Aimee E Houlton, BSc, MSc2*, Lynn Swun Quek, DPhil, FRCPath, Paul Ferguson, MBChB MRCP PhD3; Emma Gbandi, Corran Roberts (affiliation and degree needed), *, Marlen Metzner, Alison Kennedy, Manoj Raghavan4*, Sandeep Nagra1*, Louise Dudley, BSc, MRes5*, DPhil, MBBS6*, Sharon Love, Jamie D. Cavenagh7, Michael Dennis, FRCPath8*, Mary Frances McMullin, MD9, Srinivas P Pillai10*, Richard Kelly, BSc, MD11*, Shamyla Siddique12*, Keith Wheatley, DPhil13 and Paresh Vyas, BM, DPhil, FRCP, FRCPath14

Submitted

Grants: 2015-2018 Therapy Acceleration Programme &amp;pound;92 778. 
Leukaemia Lymphoma Research Funded Trial Infrastructure Programme</gtr:impact><gtr:outcomeId>56d4624608b956.62272713-1</gtr:outcomeId><gtr:partnerContribution>Clinical Trial Lead</gtr:partnerContribution><gtr:piContribution>Understanding AML Leukaemic stem cell biology. Assessment of Leukaemic stem cells (LSC) as a marker of minimal residual disease. This is evaluated using samples from clinical trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Molecular Haematology Unit</gtr:department><gtr:description>Single cell heterogeneity on normal human stem and progenitor cells</gtr:description><gtr:id>F883387B-59A7-49A0-815A-029AE5211A46</gtr:id><gtr:impact>Functional and transcriptional heterogeneity of human hemopoietic lympho-myeloid progenitors at the single cell level
Dimitris Karamitros1,2&amp;para;, Bilyana Stoilova1,2&amp;para;, Zahra Aboukhalil1, Andreas Reinisch3, Fiona Hamey4, Marina Samitsch1, Lynn Quek1,2,5, Georg Otto1, Emmanouella Repapi1, Jessica Doondea1,2, Batchimeg Usukhbayar1,2, Julien Calvo6, Stephen Taylor1, Nicolas Goardon1, Emmanuelle Six7, Francoise Pflumio6, Catherine Porcher1, Ravindra Majeti3, Berthold Gottgens4, Paresh Vyas1,2,5*

Nature Immunology Invited Revision.</gtr:impact><gtr:outcomeId>545fcd8aadace2.87630366-1</gtr:outcomeId><gtr:partnerContribution>Providing RNA-seq protocols. We will jointly analyse the data. We will jointly design follow-on functional experiments.</gtr:partnerContribution><gtr:piContribution>We have isolated primary human haemopoietic stem cell populations and are performing RNA-sequencing to begin to define the heterogeneity of these cells.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>WT Clinical Training Fellowship</gtr:description><gtr:id>60357BD8-0277-427A-86E4-F63FE515A713</gtr:id><gtr:impact>Woll PS, Kj&amp;auml;llquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, G&amp;ouml;hring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellstr&amp;ouml;m-Lindberg E, Linnarsson S, Jacobsen SE. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 25 p794-808 (2014)</gtr:impact><gtr:outcomeId>545b9af6741a66.01978794-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input and experimental design. Supervision of project.</gtr:partnerContribution><gtr:piContribution>Intellectual input and experimental design. Supervision of project.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barts Health NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Haematology</gtr:department><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>EC9D0D77-F4E3-4E28-83AB-0605FFE3D40B</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-4</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Stem Cell Institute Stanford</gtr:department><gtr:description>LSC surface antigen detection and generation of antibodies for diagnostic and therapuetic purposes</gtr:description><gtr:id>1A5B3CBD-B689-4E38-89ED-0FFCB05A8A9F</gtr:id><gtr:impact>Shared new reagents.
We have a Patent applied for.
We have MTAs with becton Dickinson, Stanford University, University of Birmingham.
Joint collaboration with Becton Dickinson and Stanford University.</gtr:impact><gtr:outcomeId>G92Jz3To1Wx-1</gtr:outcomeId><gtr:partnerContribution>Sharing of reagents.

Developing new antibodies for therapeutic and diagnostic purposes.</gtr:partnerContribution><gtr:piContribution>We have identified candidate antigens on leukaemic stem cells (LSC) in Acute Myeloid Leukaemia (AML).
We test the utility of antibodies to these antigens to detect AML LSC.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gustave-Roussy Institute</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Mutant IDH inhibition therapy in AML.</gtr:description><gtr:id>DEA66A41-3954-463D-B675-795BFBDB443B</gtr:id><gtr:impact>Grant income - 2015-2017 Celgene Fellowship in Myeloid Malignancy &amp;pound;423 141
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia
 
Eytan M. Stein, MD1*, Courtney D. DiNardo, MD2*, Daniel A. Pollyea, MD, MS3, Amir T. Fathi, MD4, Gail J. Roboz, MD5, Jessica K. Altman, MD6, Richard M. Stone, MD7, Daniel J. DeAngelo, MD, PhD7, Ross L. Levine, MD1, Ian W. Flinn, MD, PhD8, Hagop M. Kantarjian, MD2, Robert Collins, MD9, Manish R. Patel, MD10, Arthur E. Frankel, MD6, Anthony Stein, MD11, Mikkael A. Sekeres, MD, MS12, Ronan T. Swords, MD, PhD13, Bruno C. Medeiros, MD14, Christophe Willekens, MD15, Paresh Vyas, MD16,Alessandra Tosolini, BS17, Qiang Xu, PhD17, Robert D. Knight, MD17, Katharine E. Yen, PhD18, Sam Agresta, MD18, St&amp;eacute;phane De Botton, MD, PhD15?, and Martin S. Tallman, MD1? 

Submitted.
Enasidenib Induces Acute Myeloid Leukemia Cell Differentiation to Promote Clinical Response
Michael D. Amatangelo1?, Lynn Quek2?, Alan Shih3?, Eytan M. Stein3, Mikhail Roshal3, Stephane de Botton4, Benoit Marteyn5, Noushin Rahnamay Farnoud6, Muriel David7, Katharine E. Yen8, Martin S. Tallman3, Elli Papaemmanuil6,9, Virginie Lacronique-Penard4, Anjan Thakurta1*, Paresh Vyas2*, Ross L. Levine3,6,10*

Submitted.</gtr:impact><gtr:outcomeId>56d464ec73bef7.31662269-1</gtr:outcomeId><gtr:partnerContribution>Contributed samples and intellectual input</gtr:partnerContribution><gtr:piContribution>Mutant IDH inhibition therapy in AML.
Understanding mechanisms of response and resistance to targeted IDH inhibitor therapy in AML</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Becton, Dickinson and Company (BD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with the company Becton Dickinson</gtr:description><gtr:id>B0041235-3546-4169-8550-EEAAAAF68082</gtr:id><gtr:impact>There is a patent filed. Becton Dickinson has paid for the option to have first rights to licence. 

Data is not yet mature for publication. This is multidisciplinary. It involves clinical colleagues, industry, and the laboratories in Oxford and Stanford.</gtr:impact><gtr:outcomeId>C3KHzD8XsmU-1</gtr:outcomeId><gtr:partnerContribution>The company has developed a new series of monoclonal antibody reagents for FACS-based detection of leukaemic stem cells (LSC) based on our data and data in the field.

We are evaluating the commercial possibility of using a FACS-based LSC detection panel to quantitate minimal residual disease (MRD) in patients on treatment for AML.</gtr:partnerContribution><gtr:piContribution>We identified novel LSC surface antigens. We designed the panel. Both of these were done in collaboration with our colleagues in Stanford.

We have tested the panel.

We are obtaining data on patients undergoing treatment in the UK AML trials.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Metabolism and Systems Research (IMSR)</gtr:department><gtr:description>Identification of antigenic and immune determinants of graft versus leukaemia in allogeneic stem cell transplantation</gtr:description><gtr:id>3B229B24-1AEB-4508-BB47-19014FCD0AAD</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>58bfd5e260dd34.19154579-4</gtr:outcomeId><gtr:partnerContribution>Partners are contributing to the immune-specific components of the programme.</gtr:partnerContribution><gtr:piContribution>I have organised this programme.

Aim is to use WGS of AML samples, to identify AML specific variants, contrast this with donor specific exome to identify variants mis-matched between patient and donor, identify mismatched peptides expressed on AML cells that would be recognised by donor and understand the biology of an antigen-specific GvL response.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biomaterials &amp; Tissue Engineering</gtr:department><gtr:description>Identification of antigenic and immune determinants of graft versus leukaemia in allogeneic stem cell transplantation</gtr:description><gtr:id>9A670915-2DFE-45E5-9A5B-F724E7526E18</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>58bfd5e260dd34.19154579-2</gtr:outcomeId><gtr:partnerContribution>Partners are contributing to the immune-specific components of the programme.</gtr:partnerContribution><gtr:piContribution>I have organised this programme.

Aim is to use WGS of AML samples, to identify AML specific variants, contrast this with donor specific exome to identify variants mis-matched between patient and donor, identify mismatched peptides expressed on AML cells that would be recognised by donor and understand the biology of an antigen-specific GvL response.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Queen Elizabeth Medical Centre, Birmingham</gtr:department><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>3C98BC74-72FE-442A-95BA-F6511C25D396</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-2</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Childhood AML</gtr:description><gtr:id>77BD4C4D-A1A5-40A8-8B84-20065A89379E</gtr:id><gtr:impact>Initiation of the first UK childhood AML clinical trial - Mye01.
Vyas lab will be performing leukemic stem cell minimal residual disease flow cytometry analysis on sequential samples from this trial for risk stratification purposes.</gtr:impact><gtr:outcomeId>545b9a0619d536.56820283-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contribution. Contribution to some experiments.</gtr:partnerContribution><gtr:piContribution>Isolation and purification of leukaemic stem cells in childhood AML.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>WGS and additional biologic studies of haem tumours.</gtr:description><gtr:id>B855BAAF-FCF2-4FC3-B60F-AD2751C9482A</gtr:id><gtr:impact>Zabkiewicz J, Gilmour M, Hills R, Vyas P, Bone E, Davidson A, Burnett A, Knapper S. The targeted histone deacetylas inhibitor tefinostst (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget. 2016 Feb 25. doi: 10.18632/oncotarget.7692. PMID: 26934551

Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths, M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett, A and Grimwade D, for the UK National Cancer Research Institute AML Working Group. Assessment of Minimal Residual Disease in Standard Risk AML. NEJM 374 p422-33. (2016). PMID: 26789727</gtr:impact><gtr:outcomeId>56d46335697c37.53806607-2</gtr:outcomeId><gtr:partnerContribution>University of Oxford - Lead of AML GECIP (Vyas) and overall haem GECIP (Schuh)
University of Cardiff - Sponsor of Trial</gtr:partnerContribution><gtr:piContribution>Design of the program of WGS and integrated multi-&amp;quot;omic&amp;quot; reseatch program on AML UK NCRI AML clinical trial samples to define clonal structures in human AML and how they change in response to therapy. To determine molecular and cellular mechanisms of therapy resistance.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>9C5AFF24-0D80-4D66-BA9D-DE15D20D09E3</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-1</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genome editing of primary human haemopoietic stem/progenitor populations for treatment of inherited anaemias</gtr:description><gtr:id>52764545-122D-4341-9360-0B733192541F</gtr:id><gtr:impact>MRC Discovery Award</gtr:impact><gtr:outcomeId>56cdab9934fca4.39887621-1</gtr:outcomeId><gtr:partnerContribution>Higgs - dissection of alpha globin locus</gtr:partnerContribution><gtr:piContribution>Purification of human haemopoietic stem cells. Functional characterisation of haemopoietic stem cells. Testing of gene edited cells.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>Investigation of leukaemic Stem Cell biology in Childhood AML</gtr:description><gtr:id>285B32EC-5C0F-4F41-A4ED-18C5810B12DF</gtr:id><gtr:impact>No outputs yet.</gtr:impact><gtr:outcomeId>qED31tpBD9A-1</gtr:outcomeId><gtr:partnerContribution>They have studied gene expression programmes ad are developing vectors to introduce nucleic acid sequences into LSCs.</gtr:partnerContribution><gtr:piContribution>We have fractionated LSC from childhood AML samples. We are studying the molecular and genetic heterogeneity.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Haematology</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>CF0CACFB-EB1D-4772-BBF0-C562DB70EEA2</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-6</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Stem Cell Institute Stanford</gtr:department><gtr:description>Collaboration with the company Becton Dickinson</gtr:description><gtr:id>02B55159-5921-4DF6-B388-45228E81BE15</gtr:id><gtr:impact>There is a patent filed. Becton Dickinson has paid for the option to have first rights to licence. 

Data is not yet mature for publication. This is multidisciplinary. It involves clinical colleagues, industry, and the laboratories in Oxford and Stanford.</gtr:impact><gtr:outcomeId>C3KHzD8XsmU-2</gtr:outcomeId><gtr:partnerContribution>The company has developed a new series of monoclonal antibody reagents for FACS-based detection of leukaemic stem cells (LSC) based on our data and data in the field.

We are evaluating the commercial possibility of using a FACS-based LSC detection panel to quantitate minimal residual disease (MRD) in patients on treatment for AML.</gtr:partnerContribution><gtr:piContribution>We identified novel LSC surface antigens. We designed the panel. Both of these were done in collaboration with our colleagues in Stanford.

We have tested the panel.

We are obtaining data on patients undergoing treatment in the UK AML trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Radcliffe Department of Medicine</gtr:department><gtr:description>Identification of antigenic and immune determinants of graft versus leukaemia in allogeneic stem cell transplantation</gtr:description><gtr:id>7045FD68-2261-476F-B4C3-37B5C740FB86</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>58bfd5e260dd34.19154579-1</gtr:outcomeId><gtr:partnerContribution>Partners are contributing to the immune-specific components of the programme.</gtr:partnerContribution><gtr:piContribution>I have organised this programme.

Aim is to use WGS of AML samples, to identify AML specific variants, contrast this with donor specific exome to identify variants mis-matched between patient and donor, identify mismatched peptides expressed on AML cells that would be recognised by donor and understand the biology of an antigen-specific GvL response.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Christie NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Haematology and Transplant Unit</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>671B17E3-8452-466B-8320-D5E7DB5AC02F</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-7</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>AA95CAB1-A867-416C-B815-A01F61147538</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-2</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biochemistry</gtr:department><gtr:description>Role of cohesin mutations in AML</gtr:description><gtr:id>C91FB3DC-EE66-47CE-92BB-566A18568FD5</gtr:id><gtr:impact>There have been no outputs yet</gtr:impact><gtr:outcomeId>545fccd4479832.27938831-1</gtr:outcomeId><gtr:partnerContribution>They are supplying critical reagents and their understanding of Rad21 function.</gtr:partnerContribution><gtr:piContribution>We will study the haemopoietic phenotype of heterozygous loss of Rad21 and the haemopietic phenotype of combined Gata1s mutation and Rad21 heterozygous state. If there is a phenotype, we will define the mechanism for the phenotype.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>WGS and additional biologic studies of haem tumours.</gtr:description><gtr:id>9CB12E2A-7883-4526-BE0E-CFDC56FD7024</gtr:id><gtr:impact>Zabkiewicz J, Gilmour M, Hills R, Vyas P, Bone E, Davidson A, Burnett A, Knapper S. The targeted histone deacetylas inhibitor tefinostst (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget. 2016 Feb 25. doi: 10.18632/oncotarget.7692. PMID: 26934551

Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths, M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett, A and Grimwade D, for the UK National Cancer Research Institute AML Working Group. Assessment of Minimal Residual Disease in Standard Risk AML. NEJM 374 p422-33. (2016). PMID: 26789727</gtr:impact><gtr:outcomeId>56d46335697c37.53806607-1</gtr:outcomeId><gtr:partnerContribution>University of Oxford - Lead of AML GECIP (Vyas) and overall haem GECIP (Schuh)
University of Cardiff - Sponsor of Trial</gtr:partnerContribution><gtr:piContribution>Design of the program of WGS and integrated multi-&amp;quot;omic&amp;quot; reseatch program on AML UK NCRI AML clinical trial samples to define clonal structures in human AML and how they change in response to therapy. To determine molecular and cellular mechanisms of therapy resistance.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Haematology</gtr:department><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>5B08CE30-4478-4383-A251-0ACE45EB48A6</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-3</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Haematology</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>ADABB80D-E438-4C5B-A1A6-85A61AFDAD54</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-5</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Population Medicine</gtr:department><gtr:description>Identification of antigenic and immune determinants of graft versus leukaemia in allogeneic stem cell transplantation</gtr:description><gtr:id>74889C4A-06B6-484A-B5BB-425F8EEA0E9D</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>58bfd5e260dd34.19154579-3</gtr:outcomeId><gtr:partnerContribution>Partners are contributing to the immune-specific components of the programme.</gtr:partnerContribution><gtr:piContribution>I have organised this programme.

Aim is to use WGS of AML samples, to identify AML specific variants, contrast this with donor specific exome to identify variants mis-matched between patient and donor, identify mismatched peptides expressed on AML cells that would be recognised by donor and understand the biology of an antigen-specific GvL response.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Celgene</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Mutant IDH inhibition therapy in AML.</gtr:description><gtr:id>E663B824-8A90-4609-A96B-EAE3E0C2E24C</gtr:id><gtr:impact>Grant income - 2015-2017 Celgene Fellowship in Myeloid Malignancy &amp;pound;423 141
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia
 
Eytan M. Stein, MD1*, Courtney D. DiNardo, MD2*, Daniel A. Pollyea, MD, MS3, Amir T. Fathi, MD4, Gail J. Roboz, MD5, Jessica K. Altman, MD6, Richard M. Stone, MD7, Daniel J. DeAngelo, MD, PhD7, Ross L. Levine, MD1, Ian W. Flinn, MD, PhD8, Hagop M. Kantarjian, MD2, Robert Collins, MD9, Manish R. Patel, MD10, Arthur E. Frankel, MD6, Anthony Stein, MD11, Mikkael A. Sekeres, MD, MS12, Ronan T. Swords, MD, PhD13, Bruno C. Medeiros, MD14, Christophe Willekens, MD15, Paresh Vyas, MD16,Alessandra Tosolini, BS17, Qiang Xu, PhD17, Robert D. Knight, MD17, Katharine E. Yen, PhD18, Sam Agresta, MD18, St&amp;eacute;phane De Botton, MD, PhD15?, and Martin S. Tallman, MD1? 

Submitted.
Enasidenib Induces Acute Myeloid Leukemia Cell Differentiation to Promote Clinical Response
Michael D. Amatangelo1?, Lynn Quek2?, Alan Shih3?, Eytan M. Stein3, Mikhail Roshal3, Stephane de Botton4, Benoit Marteyn5, Noushin Rahnamay Farnoud6, Muriel David7, Katharine E. Yen8, Martin S. Tallman3, Elli Papaemmanuil6,9, Virginie Lacronique-Penard4, Anjan Thakurta1*, Paresh Vyas2*, Ross L. Levine3,6,10*

Submitted.</gtr:impact><gtr:outcomeId>56d464ec73bef7.31662269-2</gtr:outcomeId><gtr:partnerContribution>Contributed samples and intellectual input</gtr:partnerContribution><gtr:piContribution>Mutant IDH inhibition therapy in AML.
Understanding mechanisms of response and resistance to targeted IDH inhibitor therapy in AML</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Haematology</gtr:department><gtr:description>Downs Syndrome associated preleukaemia and leukaemia</gtr:description><gtr:id>7FE8CDE2-62F8-46B5-8EFF-205EB9DB14EC</gtr:id><gtr:impact>Grants 2008 Leukaemia Research 5-year Programme Grant, &amp;pound;1.03 M Publications (PubMed ID below): 19594743 18242315 18689547 18059480 18625887 17804520 17644747 17224656 17064858</gtr:impact><gtr:outcomeId>BECB8F52244-1</gtr:outcomeId><gtr:partnerContribution>We have a joint programme of work including a joint LLR Programme grant</gtr:partnerContribution><gtr:piContribution>We provide the majority of the research effort in this collaborative programme. We study the molecular and cellular basis of leukaemia using patient samples and mouse models that we are generating.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Lynn Quek  - Celgene Platform for the Exchange of Expertise and Research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>96883370-B253-4BFD-B94E-939E2CDE50DB</gtr:id><gtr:impact>Talk about Translational Research in Haematology at the Celgene Platform the Exchange of Expertise and Research</gtr:impact><gtr:outcomeId>58c01020b50e02.87389803</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Week</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C64B1995-9E06-4450-98FF-20BE60D0D3F6</gtr:id><gtr:impact>Oxford Science Week is held annually to an audience of scientists and the general public.

Good feedback from schools</gtr:impact><gtr:outcomeId>67D8B48106B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Open Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>99F3A55E-290A-43A3-81E3-3A8B287BF8C8</gtr:id><gtr:impact>88 members of the general public attended a series of short presentations and Question and Answer session on what benefit research plays in advancing health.

Positive feedback and a request for annual repeat of the session</gtr:impact><gtr:outcomeId>p7pT6cTwu7w</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Student Presentations</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1E7F901D-F759-4FAE-8050-F2586F1B39BA</gtr:id><gtr:impact>Final year students present their work to the members of the Weatherall Institute of Molecular Medicine. This presentation day is held annually.

Improved student training.</gtr:impact><gtr:outcomeId>F30E22D719D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview with television</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8ACF8E02-D76B-4DF7-A12C-1892763CA1F7</gtr:id><gtr:impact>I gave a 3 minute interview screened on ITV Central New bulletin at 6 pm and 10 pm.

Public interest in drug trials in leukaemia</gtr:impact><gtr:outcomeId>Gt2TRGoU5rD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Oxford Radio Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EC96E42E-8ED1-4273-A446-8D713DF46A2E</gtr:id><gtr:impact>Discussion on public access to new drugs made possible by research

Increased local awareness of clinical trials funded by academic funded research</gtr:impact><gtr:outcomeId>jkKJFbtrpKn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lynn Quek - UK MDS Forum</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BE9440A0-C132-42EC-980F-21D4903EDE62</gtr:id><gtr:impact>Talk on Differentiation Block in AML at the UK MDS Forum.</gtr:impact><gtr:outcomeId>58c00f28398e81.04092762</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Video for patients</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>21D79C57-556B-4310-9EF0-4C59D21D8334</gtr:id><gtr:impact>Made a video for patients to explain the symptoms and signs of Myelodysplasia and some of the treatments available

Increased patient awareness
Led in part to the petition to Parliament to reclassify MDS as a cancer</gtr:impact><gtr:outcomeId>X78kmiXXMLA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NSSG Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AAF6A806-A7C9-4C80-84C5-F12C6F376DFB</gtr:id><gtr:impact>Talked at meeting for 50 people, mainly an audience of Professional Practitioners and Admin Staff.</gtr:impact><gtr:outcomeId>58c124a31ded76.04140472</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>175487</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PADI2 inhibitior as a therapy targeting acute myeloid leukemia initiating cells</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>7BEB503B-A3C0-41D1-9B7F-309BFB925BD4</gtr:id><gtr:outcomeId>5876391637cc37.48971627</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>440000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Programme Grant</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>1FEEE828-8834-4018-A216-12C93723AA28</gtr:id><gtr:outcomeId>hT2syNvbftE0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1369070</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLR, Programme Grant</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>56EA897C-0B30-4467-A4B5-2FC04A51BB86</gtr:id><gtr:outcomeId>56cd76501969d4.75789206</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49234</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust, ISSF - Institutional Strategic Support Fund</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>E305E2C6-70F4-4592-90F4-5154F93B9289</gtr:id><gtr:outcomeId>56cd722fa4db50.83959002</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>423140</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Celgene Corp (USA) Celgene funded post-doctoral fellowship programme</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Celgene</gtr:fundingOrg><gtr:id>8D16415B-5748-4B1B-BA19-AEC5BB06A320</gtr:id><gtr:outcomeId>56cd73621613b1.66326939</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>Haematology and Stem Cell Theme Oxford Biomedical Research Centre (NIHR)</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>3FA28EB9-7FE9-4421-AA16-52B4DE8AC55A</gtr:id><gtr:outcomeId>58bfd91beaf544.69148880</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>195016</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLR Project Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>8A7E2511-B325-45A0-8150-96D3301E5482</gtr:id><gtr:outcomeId>Y1B9McnmjDW</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19845</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Understanding heterogeneity of treatment response in 'standard' risk acute myeloid leukaemia</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Bloodwise</gtr:fundingOrg><gtr:id>282C5A43-046B-4409-8754-873D5661D876</gtr:id><gtr:outcomeId>58763862d71061.28096815</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>218356</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT CLinical Training Fellowship</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>889DFE25-270F-4110-86A9-BC26EFBE5583</gtr:id><gtr:outcomeId>RtNxf8hvoKS</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>174000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Celgene PhD Studentship</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Celgene</gtr:fundingOrg><gtr:id>628C6A42-B4D2-40A7-87E9-01A4D0E5C0AB</gtr:id><gtr:outcomeId>F10F7B4B6040</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>780000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Oxford BRC - Joint Application</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>3D08341A-30A1-4896-89C3-A8F57457D1BE</gtr:id><gtr:outcomeId>EB395yXaYqA</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>520000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Molecular Haematology Unit Award</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>493E2D0C-75C7-4526-80C7-78D9679F2057</gtr:id><gtr:outcomeId>gtvjc4DAy2Y</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1378340</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Lymphoma Research Programme Grant</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>778DE30C-0857-48D0-9CA7-49F6FD33B39A</gtr:id><gtr:outcomeId>CwoS9rev3jD</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2009 Disease Team Award</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1027AF50-E443-4B9D-ADB8-3BCE26B28419</gtr:id><gtr:outcomeId>55756B3EA280</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Immunophenotypic detection of AML LSC</gtr:description><gtr:grantRef>MC_UU_12009/11</gtr:grantRef><gtr:id>933A3406-7503-461F-9BFB-E7ACA645EFD8</gtr:id><gtr:impact>We are developing a commercial product with the company BD</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>WSjAyBYMFZ3</gtr:outcomeId><gtr:patentId>WO2012085574</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Immunophenotypic detection of AML LSC</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Monitoring of Acute Myeloid Leukaemia stem cells (LSC) in patients receiving treatment</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>88D37358-DAE4-4BAE-A448-9E8F3196500F</gtr:id><gtr:impact>Our protocol of monitoring AML LSC has changed national practice. This is now routine for UK AML trials that recruit 95% of all UK AML patients under 60 years old.</gtr:impact><gtr:outcomeId>D9156B99097</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>LSC detection is now part of the UK AML trial laboratory studies fro MRD detection</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B8383159-DB73-49DE-9B4D-BA5FE98AAEB3</gtr:id><gtr:impact>The change if validated over the next 2-3 years will transform the detection of residual leukaemia post therapy and have implication for the necessity of additional post remission therapy. There will be implications for other cancers as a whole.</gtr:impact><gtr:outcomeId>rrnG4YjcDkr</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Geoff Thomas Foundation</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3FC65708-4787-4888-B39F-E3AD72D70491</gtr:id><gtr:impact>Prof Vyas has advised the Geoff Thomas Foundation (GTF) (http://www.geoffthomasfoundation.org/site/index.php) - a Football Association (FA) charity raising money and awareness to fight blood cancers. Dr Vyas has attended meetings with parliamentarians, research funders (CRUK, LR and DoH) with Geoff Thomas Foundation. There was a successful application to the Leukaemia and Lymphoma Research Clinical Trials Advisory Panel (http://www.lrf.org.uk/en/1/scirespan.html), with support from GTF to raise funding for national clinical trials group for early phase trials in blood cancers.</gtr:impact><gtr:outcomeId>4F63C5D0932</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type><gtr:url>http://www.geoffthomasfoundation.org/site/index.php</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>UK Clinical Guidelines on the Treatment of Myelodysplasia</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>423379F8-8527-4BE3-9F78-A93E8280272F</gtr:id><gtr:outcomeId>MtisqXmiV4r</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>IMPACT - Transplantation Trials Practice</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>74C8BFA8-2966-45C3-B372-315413CEAE90</gtr:id><gtr:outcomeId>58c00b4af33c92.06412858</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>UK Stem Cell Strategic Forum</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9B29F85B-068B-47F2-BEEA-9B3C84B6A79B</gtr:id><gtr:impact>Provided evidence on how to structure research and development using blood stem cells for a Report commissioned by DoH and involving NHSBT, Anthony Nolan Trust, DoH, Lead clinicians in Bone Marrow transplantation and members of the Devolved Administrations.</gtr:impact><gtr:outcomeId>tfHTGM3BPTK</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>We are testing the clinical utility of this product</gtr:description><gtr:id>79E0935D-968B-4F6A-8952-3A1418181A93</gtr:id><gtr:impact>We have developed a new flow cytometric test of measurable residual disease in patients with Acute Myeloid Leukaemia.</gtr:impact><gtr:outcomeId>SNTZYzr59vV</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Detection of minimal residual disease in AML</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Multi-center, Open-label, Phase I Study of Single Agent RO5045337 Administered Orally In patients with Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) In Blast Phase, Or Refractory Chronic Lymphocytic leukemia/Small Cell Lymphocytic Lymphoma (CLL/SCLL). 

Vyas was local PI.</gtr:description><gtr:id>07CD7463-5A14-44BB-9718-96A314B3C9DD</gtr:id><gtr:impact>Phase II trials started.</gtr:impact><gtr:outcomeId>56d5d72fef9be6.62617810</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Roche RO504337 in Acute Leukaemia</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>623870</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We have developed technology to monitor AML LSCs in all patients treated in UK AML NCRN (National Cancer Regional Network) Trials at diagnosis and following treatment.</gtr:description><gtr:id>58C8018A-A414-49D7-BE49-D7BA4850FB57</gtr:id><gtr:impact>This technology has been transferred to the NHS.</gtr:impact><gtr:outcomeId>9E5149294A4</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Monitoring AML leukaemic stem cells</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral A-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)


Vyas is UK CI.</gtr:description><gtr:id>07C7D54C-385E-4375-AC5A-420F0630AEDB</gtr:id><gtr:impact>Impact awaited.</gtr:impact><gtr:outcomeId>56d5d6fa606997.50080069</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>AG221 AML-005:</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase 3, Multicenter, Randomized, Open-label, Study Of Azacitidine Versus Conventional Care Regimens For The Treatment Of Older Subjects With Newly Diagnosed Acute Myeloid Leukaemia. 

Vyas was local PI.</gtr:description><gtr:id>D2D9CB18-EE51-4E5B-8415-37593EE8DCEB</gtr:id><gtr:impact>Has led to EMA licence for Aza for AML. NICE refused to fund under TA. Celgene will put forward a patient access scheme for UK patients.</gtr:impact><gtr:outcomeId>56d5d635345789.43269027</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Celgene Aza-AML-001:</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A multi-center, randomized, double-blind, placebo- controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload (TELESTO)

International Phase III trial of an oral iron chelator in Myelodsplastic Syndrome. Sponsored by Novartis. Vyas is UK CI.</gtr:description><gtr:id>EE6D0BA0-A851-446D-9552-B29E417482D4</gtr:id><gtr:impact>Impact awaited. Trial data closed and data being analysed.</gtr:impact><gtr:outcomeId>56d5d5b1426b82.74769642</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Novartis Telesto Trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase III UK AML trials: AML 19, LI1. Vyas is Lead for Genome England Program and flow cytometric leukaemic stem cell MRD studies.</gtr:description><gtr:id>CF454681-E128-4D23-BCF3-214C7C26026D</gtr:id><gtr:impact>PV to write</gtr:impact><gtr:outcomeId>56d5564942bb58.57417433</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>UK AML NCRI Working Group AML 17, AML 18, AML 19 and LI1.</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>AML 17 - 55675535 , AML18 - 31682779 , AMl 19 78449203 , LI1 18218</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>UK NCRI Group Phase III trial of therapy in children with AML. Vyas is lead on AML leukaemic stem cell studies.</gtr:description><gtr:id>D755A6FA-12B7-4B73-8C34-1698C340C754</gtr:id><gtr:impact>First UK Childhood AMl trial. Vyas is LSC lead</gtr:impact><gtr:outcomeId>56d555f75a0e81.84126205</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Myechild 01</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase 1 trial of Romidepsin plus Azacitidine Combination Therapy In Patients With Newly Diagnosed, Relapsed Or Refractory Acute Myeloid Leukaemia Ineligible For Salvage Chemotherapy. Vyas is co-Investigator and Scientific Lead.</gtr:description><gtr:id>1A003D19-880C-4BBF-8EE3-D1849C7AE4EC</gtr:id><gtr:impact>This trial, together with others in the portfolio establish the Bloodwsie funded Therapy Accelration Program (TAP) as the vechicle for early Phase AML and MDS clinical trial delivery through 15 major UK University-NHS teaching hospitals. I am scientific lead of the TAP program and play a leading role in trial design.</gtr:impact><gtr:outcomeId>56d46bcb3f4335.71621306</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ROMAZA</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Phase 3, Multicenter, Randomized, Double-blind Study To Compare The Efficacy And Safety Of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due To IPSS Lower-risk Myelodysplastic Syndromes. Vyas is UK national CI.</gtr:description><gtr:id>34E0B085-0E2B-4EF9-92D0-8D50D9607999</gtr:id><gtr:impact>This Phase III licencing study will provide clincial dataset that could potential licence oral Azacitidine.</gtr:impact><gtr:outcomeId>56d5568805ef03.05348475</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Celgene MDS003</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG-221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATIO International Phase III trial of a first-in-class oral IDH2 inhibitor in Acute Myeloid Leukaemia. Sponsored by Celgene. Vyas is UK CI.</gtr:description><gtr:id>39D2E445-BC48-45A0-8A53-F592E9A477F5</gtr:id><gtr:impact>Impact still awaited.</gtr:impact><gtr:outcomeId>56d556e6dfc655.80450036</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>IDH2 inhibitor trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase II Randomised Trial of 5-Azacitidine versus 5- Azacitidine in combination with Vorinostat in patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy). 250 patients. Fully recruited. Vyas is co-Investigator and Scientific Lead.

Trial completed. Manuscript submitted.</gtr:description><gtr:id>19BCA468-B8CD-498F-A187-52FA6FECAA6D</gtr:id><gtr:impact>This trial is helping to define azacitidine based combination therapies.</gtr:impact><gtr:outcomeId>56d55564301a84.76477516</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>RavVa trial:</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating The Efficacy And Safety of Azacitidine Subcutaneous In Combination with Durvalumab (MEDIA4736) In Previously Untreated subjects With Higher-risk Myelodysplastic Syndromes (MDS) Or In Elderly (= 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible For Hematopoietic Stem Cell Transplantation (HSCT). Vyas is local PI.</gtr:description><gtr:id>2D17C4D8-3C77-41B0-9C5B-CAFB209CC2CC</gtr:id><gtr:impact>Impact awaited</gtr:impact><gtr:outcomeId>56d5d5747686f5.85501777</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Evaulation of anti-PD-L1 in high risk MDS and AML.</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial Of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care For The Treatment of Myelodysplastic Syndromes (MDS). 

Vyas is local PI.</gtr:description><gtr:id>5C5F1FEA-F6D2-4C9E-8273-2BBA326988F7</gtr:id><gtr:impact>Led to licencing of Aza for MDS. NICE approved drug. Now standard of care for this patient group.</gtr:impact><gtr:outcomeId>56d5d5f60e2b13.75372260</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Celgene Aza-MDS-001:</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed secure web-based databases of clinical data associated with 439 bone marrow samples taken from patients with diseases affecting myeloid blood cells (Leukaemia and pre-leukaemia disorders). Clinical details are now automatically entered from collaborating NHS Trusts under approved protocols. The clinical data is linked to secure web-based databases containing detailed molecular, cellular and functional characterisation of stem and progenitor blood compartments from patient samples.</gtr:description><gtr:id>142D749A-989D-4AD5-85E3-6247AB4BA48F</gtr:id><gtr:impact>This has allowed us to publish papers (PubMed IDs below) and secure the MRC Disease Team Award. PubMed IDs 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>E6ECEF4F618</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Clinical and biological database of myeloid diseases</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19664981</gtr:url><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Jointly with the WIMM single cell facility we are developing novel methods to analyse the total complement of a cell's nucleic acid and anlsyse chromatin structure.</gtr:description><gtr:id>3E9AF27E-6D35-47BB-A085-4034D8EC2B16</gtr:id><gtr:impact>Multiple research projects have been developed from these tools.</gtr:impact><gtr:outcomeId>58bfdcf0660ee4.85523981</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Improving single cell biology</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed technology to monitor AML LSCs in all patients treated in UK AML NCRN (National Cancer Regional Network) Trials at diagnosis and following treatment.</gtr:description><gtr:id>820BB5F6-2166-4EEB-84CD-2CD792B5F3B2</gtr:id><gtr:impact>This technology has been transferred to the NHS. For the first time, this study will determine if eradication cancer stem cells is required to cure cancer.</gtr:impact><gtr:outcomeId>54EB5C14992</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Fluorescence activated cell sort based protocol to monitor Acute Myeloid Leukaemia stem cells (LSCs).</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Collection of 3000 frozen viable cells patients with AML and Myelodysplasia (MDS) a preleukaemic form of AML.</gtr:description><gtr:id>8DF4141B-653C-4B70-837D-5547855131BE</gtr:id><gtr:impact>2 papers in NEJM and 3 paper in BLood 2 in Leukaemia</gtr:impact><gtr:outcomeId>B2eqkbAUeNZ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Bone marrow cells</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New antibodies to detect AML LSC</gtr:description><gtr:id>0DAD2632-9609-4331-8BD3-8BBD6C6596E1</gtr:id><gtr:impact>Evaluation of the use of this research material is still in progress</gtr:impact><gtr:outcomeId>Z6mwhGtHpgB</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>New antibodies to detect AML LSC</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6C8A02EE-44E7-46C4-9140-64D4819772E4</gtr:id><gtr:title>GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b244db03523acfcca3e96a5f37df371"><gtr:id>8b244db03523acfcca3e96a5f37df371</gtr:id><gtr:otherNames>Roberts I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_24021668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DADD290B-BD96-476A-85B3-FDFF58C689FB</gtr:id><gtr:title>Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70d30a423e81944842cc60515ff69f8c"><gtr:id>70d30a423e81944842cc60515ff69f8c</gtr:id><gtr:otherNames>Quek L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>585d379f003b40.39295341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>366BD48D-472B-4134-B280-081406D7C672</gtr:id><gtr:title>Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a4de4f25ab06ec8486a5297e7e5328d"><gtr:id>3a4de4f25ab06ec8486a5297e7e5328d</gtr:id><gtr:otherNames>Goardon N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>NXnc8v2fhRL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06F31FFE-F47A-4BBF-B481-383725586B72</gtr:id><gtr:title>Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fe1d78d9f73909aa0285fb1be6f87e2"><gtr:id>9fe1d78d9f73909aa0285fb1be6f87e2</gtr:id><gtr:otherNames>Mussai F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_23733335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76768982-7957-4459-A0D3-6C956B3CBE72</gtr:id><gtr:title>Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.</gtr:title><gtr:parentPublicationTitle>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00223d0cb2f2c2b62ce0eb3ce2a48d21"><gtr:id>00223d0cb2f2c2b62ce0eb3ce2a48d21</gtr:id><gtr:otherNames>Craddock C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1083-8791</gtr:issn><gtr:outcomeId>56bdddd62d42c1.28157746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11262BC5-BD22-4DA0-BD54-D9170EB0CC1F</gtr:id><gtr:title>Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0595a7d8bf7c30b67c83c71fcc8d9e98"><gtr:id>0595a7d8bf7c30b67c83c71fcc8d9e98</gtr:id><gtr:otherNames>Taylor JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>56bddf9566b4b5.02704625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF79350B-25E5-4C77-96FF-7A1A3C6ACC3C</gtr:id><gtr:title>GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56314d300d185f04fed4e5d838e1f1b"><gtr:id>d56314d300d185f04fed4e5d838e1f1b</gtr:id><gtr:otherNames>Maroz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>5453ac3faf2d49.24194245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9AE5928-9CBE-4011-9108-76D3A65723F7</gtr:id><gtr:title>Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.</gtr:title><gtr:parentPublicationTitle>Leukemia research reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a64354cef682d91105e2c9e80246794"><gtr:id>8a64354cef682d91105e2c9e80246794</gtr:id><gtr:otherNames>Dennis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2213-0489</gtr:issn><gtr:outcomeId>5453ac227134a6.61951535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4000E9FE-24F9-4EC6-B497-E4E959308659</gtr:id><gtr:title>Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de1abc4561036fa0e5e1f464b54dd8b7"><gtr:id>de1abc4561036fa0e5e1f464b54dd8b7</gtr:id><gtr:otherNames>Craddock CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>5a609e6e245948.48173958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>537B66C4-0EAD-460F-97E9-C5BF89FDAD4B</gtr:id><gtr:title>Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d776866a5dee0d8e2f2f02303fedd07"><gtr:id>0d776866a5dee0d8e2f2f02303fedd07</gtr:id><gtr:otherNames>Eyre T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_23175662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BAF2E38-0E34-4739-A1CC-188F98706165</gtr:id><gtr:title>Persistent malignant stem cells in del(5q) myelodysplasia in remission.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a96d892dd559c3e7d3575f4ae7396778"><gtr:id>a96d892dd559c3e7d3575f4ae7396778</gtr:id><gtr:otherNames>Tehranchi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>SW3AQLMqaZL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E4AAB62-A3D0-449B-A115-64812E13670B</gtr:id><gtr:title>Lineage-specific combinatorial action of enhancers regulates mouse erythroid Gata1 expression.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c898c712828706075492c628cb10fce"><gtr:id>5c898c712828706075492c628cb10fce</gtr:id><gtr:otherNames>Drissen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>TohnmM93RcU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C838B31-0369-4CD7-9739-2D4FA2E86DFC</gtr:id><gtr:title>Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a4de4f25ab06ec8486a5297e7e5328d"><gtr:id>3a4de4f25ab06ec8486a5297e7e5328d</gtr:id><gtr:otherNames>Goardon N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>E410953F0D4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>418C9929-1275-45F5-ACBA-4D7D4A539F8D</gtr:id><gtr:title>Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Blood advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70d30a423e81944842cc60515ff69f8c"><gtr:id>70d30a423e81944842cc60515ff69f8c</gtr:id><gtr:otherNames>Quek L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2473-9529</gtr:issn><gtr:outcomeId>58a6ce037478c0.00362794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC55A6B3-A53D-4168-9108-1B76674C69D1</gtr:id><gtr:title>Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb2ab2f26a8b32097ed7b56cf62d517d"><gtr:id>fb2ab2f26a8b32097ed7b56cf62d517d</gtr:id><gtr:otherNames>Andreeff M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>56bddec41c15c3.45328013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>061D1275-7180-4AE5-B809-1038F7F1D355</gtr:id><gtr:title>Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4565dafaf87d213d5e13e790513349db"><gtr:id>4565dafaf87d213d5e13e790513349db</gtr:id><gtr:otherNames>Khan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58a6cd8d5e6bd3.58648337</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9577A0A-CE20-4FAC-BFBD-2A6DBD810C4F</gtr:id><gtr:title>The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9527bfcbdb625e348951bfb95a09345f"><gtr:id>9527bfcbdb625e348951bfb95a09345f</gtr:id><gtr:otherNames>Yip BH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>5a609dfd39b5b6.18693941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2086DAA-F14A-4FDD-9839-B3494CFFD166</gtr:id><gtr:title>FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_15590_20_23727242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7F43648-5E6C-4F62-80FB-95A4934C02E4</gtr:id><gtr:title>Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00223d0cb2f2c2b62ce0eb3ce2a48d21"><gtr:id>00223d0cb2f2c2b62ce0eb3ce2a48d21</gtr:id><gtr:otherNames>Craddock C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_15590_20_23223186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90CD96BB-6E49-4C19-B065-6E885130E79D</gtr:id><gtr:title>Enasidenib in mutantrelapsed or refractory acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfbb54f62d263d00cd911b08033c95e2"><gtr:id>cfbb54f62d263d00cd911b08033c95e2</gtr:id><gtr:otherNames>Stein EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a609e56b22214.51272307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A164AE0-0089-4F4A-A237-DD96B56126E8</gtr:id><gtr:title>Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5eb6709aee32b4deee2432c393eec70"><gtr:id>c5eb6709aee32b4deee2432c393eec70</gtr:id><gtr:otherNames>Schuurhuis GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a93d1b70879c6.87730594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6A99983-720F-443D-99EA-25419B047F58</gtr:id><gtr:title>Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2ff93192dec71a3af4d8933d02728f3"><gtr:id>f2ff93192dec71a3af4d8933d02728f3</gtr:id><gtr:otherNames>Gu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>56bdde009da852.13252225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DC1225B-E4B1-448A-A39A-6056870FA5A0</gtr:id><gtr:title>Assessment of minimal residual disease in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Current opinion in oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa63804623afefe42d3849f6aead48b0"><gtr:id>fa63804623afefe42d3849f6aead48b0</gtr:id><gtr:otherNames>Grimwade D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1040-8746</gtr:issn><gtr:outcomeId>Xu1FpEEHAbW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>690E417F-DEC1-4B17-952B-A5ECEA1D0BC6</gtr:id><gtr:title>Prenatal therapy in transient abnormal myelopoiesis: a systematic review.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood. Fetal and neonatal edition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73ab14008cb33c7de3145123dad84a70"><gtr:id>73ab14008cb33c7de3145123dad84a70</gtr:id><gtr:otherNames>Tamblyn JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-2998</gtr:issn><gtr:outcomeId>56bddd9f9d6945.19596302</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>858206AC-275C-46DC-9A05-A5F5553C92AA</gtr:id><gtr:title>The impact of trisomy 21 on early human hematopoiesis.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4f5d0920d73a0a7caca3b42bf26d5a4"><gtr:id>f4f5d0920d73a0a7caca3b42bf26d5a4</gtr:id><gtr:otherNames>Roy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>pm_15590_20_23343767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>928679F2-2089-4C4B-A691-97D4B977B139</gtr:id><gtr:title>Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Blood advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd65476392b651a10fba13097d3382a4"><gtr:id>bd65476392b651a10fba13097d3382a4</gtr:id><gtr:otherNames>Kinstrie R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2473-9529</gtr:issn><gtr:outcomeId>58a6ce671c0613.84723302</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0EDB52F-ADCA-4107-B292-D27ED8A63E55</gtr:id><gtr:title>Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc665401f5b0d46333c809dc8a502fb1"><gtr:id>fc665401f5b0d46333c809dc8a502fb1</gtr:id><gtr:otherNames>Amatangelo MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a609e3d9eccb1.20262709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9120F0C0-C8F8-4BE0-B6DE-645DA994141C</gtr:id><gtr:title>Guidelines for the diagnosis and management of adult myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eae682c909e2ede9e072ba471ecfdd6c"><gtr:id>eae682c909e2ede9e072ba471ecfdd6c</gtr:id><gtr:otherNames>Killick SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5453ac56c61674.95273082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D212EF9-8DE2-453B-98CE-829A676E4517</gtr:id><gtr:title>Uncoupling VEGFA functions in arteriogenesis and hematopoietic stem cell specification.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e3074d3fc43b0c44b68d9cfe2dfd095"><gtr:id>1e3074d3fc43b0c44b68d9cfe2dfd095</gtr:id><gtr:otherNames>Leung A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>pm_15590_20_23318133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B74F68CF-DB39-49C4-8657-9FFC00DDEEC6</gtr:id><gtr:title>Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de95b72cde69d3a1a807171fad58b602"><gtr:id>de95b72cde69d3a1a807171fad58b602</gtr:id><gtr:otherNames>Jan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_15590_20_22932223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B87694D4-2D14-4F15-899C-9AC7DC56CB63</gtr:id><gtr:title>The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc064c75b61121bfd0291c56cc975561"><gtr:id>fc064c75b61121bfd0291c56cc975561</gtr:id><gtr:otherNames>Zabkiewicz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5876321b848e14.62502450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AB15675-3754-4ACE-949E-CB9EE72FCCB3</gtr:id><gtr:title>The impact of trisomy 21 on foetal haematopoiesis.</gtr:title><gtr:parentPublicationTitle>Blood cells, molecules &amp; diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b244db03523acfcca3e96a5f37df371"><gtr:id>8b244db03523acfcca3e96a5f37df371</gtr:id><gtr:otherNames>Roberts I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1079-9796</gtr:issn><gtr:outcomeId>pm_15590_20_23932236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9D3897A-C003-41C5-A53F-160EAB292D30</gtr:id><gtr:title>Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12537c288d6c1ba53d85304b509ec742"><gtr:id>12537c288d6c1ba53d85304b509ec742</gtr:id><gtr:otherNames>Della Porta MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_15590_20_22315489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76BEB17C-5B5C-44B0-AD42-555F9BFA6D82</gtr:id><gtr:title>Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e0b20cfc0518dfe2421077726527510"><gtr:id>8e0b20cfc0518dfe2421077726527510</gtr:id><gtr:otherNames>Karamitros D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>5a609e858339b8.50318694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32595494-3346-488C-AD11-BFC84168FB0C</gtr:id><gtr:title>Clinical and biological implications of driver mutations in myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4c954d767ba92727eabc85d0b700988"><gtr:id>c4c954d767ba92727eabc85d0b700988</gtr:id><gtr:otherNames>Papaemmanuil E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_24030381</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B493A2D3-CCE9-4277-B0B2-2629EB4C635D</gtr:id><gtr:title>Impact of isolated germline JAK2V617I mutation on human hematopoiesis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_23535062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F8A7596-29CC-4C51-AC09-E4C183F6BEA9</gtr:id><gtr:title>Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a017171bc87b2f6382042a9f9a3a08be"><gtr:id>a017171bc87b2f6382042a9f9a3a08be</gtr:id><gtr:otherNames>El Omari K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_15590_20_23831025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BB37566-C3EF-4262-A451-D530DA81E817</gtr:id><gtr:title>Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab8e8f7d43db2d02f8fbaf90a095239"><gtr:id>4ab8e8f7d43db2d02f8fbaf90a095239</gtr:id><gtr:otherNames>Giustacchini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>5a609e1f3c7d99.44299737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F3B7D12-B308-4324-BD3E-6EE5845E4EB5</gtr:id><gtr:title>Characterization of the hemopoietic defect in early stages of the myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>Advances in enzyme regulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3545a0abfc060e990dc3441ab241c85"><gtr:id>c3545a0abfc060e990dc3441ab241c85</gtr:id><gtr:otherNames>Vyas P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0065-2571</gtr:issn><gtr:outcomeId>38BCAB28E7C</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12009/11</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>